CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation of preclinical data of CS2009 ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A ...

An already approved cancer drug, Yervoy (ipilimumab), improved lung repair ability in a study of mice with idiopathic ...

However, a group of American scientists claim a cancer drug already used by the Health Service can reverse damage caused by ...

2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation of preclinical data of CS2009 (PD-1/VEGF/CTLA-4 trispecific ...